Skip to main content
Journal cover image

Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study.

Publication ,  Conference
Parrish, KM; Thomas, SM; Cartwright, SB; van den Bruele, AB; Zasloff, R; DiLalla, GA; DiNome, ML; Menendez, CS; Rosenberger, LH; Woriax, HE ...
Published in: Ann Surg Oncol
November 2024

BACKGROUND: Patients with inflammatory breast cancer (IBC) have worse survival compared with stage III non-IBC matched cohorts; however, the prognostic significance of achieving pathologic complete response (pCR) in the setting of IBC is not well described. We evaluated overall survival (OS) between IBC patients and non-IBC patients who achieved pCR. METHODS: Adult females diagnosed in 2010-2018 with clinical prognostic stage III unilateral invasive breast cancer treated with neoadjuvant chemotherapy (NAC) followed by surgery were selected from the National Cancer Database. Unadjusted OS from surgery was estimated using the Kaplan-Meier method, and log-rank tests were used to compare groups. Cox proportional hazard models were used to estimate the association of study groups with OS after adjustment for available covariates. RESULTS: The study included 38,390 patients; n = 4600 (12.0%) IBC and n = 33,790 (88.0%) non-IBC. Overall pCR rates were lower for IBC compared with non-IBC (20.7% vs. 23.3%; p < 0.001). Among those achieving pCR, 5-year mortality was higher for IBC patients (16.4%, 95% confidence interval [CI] 13.9-19.1%) versus non-IBC patients (9.1%, 95% CI 8.4-9.8%; log-rank p < 0.001). Among all patients achieving pCR, IBC remained associated with worse OS compared with non-IBC (hazard ratio 1.48, 95% CI 1.19-1.85; p < 0.001). CONCLUSION: We found a lower pCR rate and worse OS in IBC patients compared with non-IBC stage III patients. Despite effective systemic therapies, achieving a pCR for IBC patients may not carry the same prognostic impact compared with non-IBC stage III patients.

Duke Scholars

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

November 2024

Volume

31

Issue

12

Start / End Page

8057 / 8067

Location

United States

Related Subject Headings

  • Survival Rate
  • Retrospective Studies
  • Prognosis
  • Pathologic Complete Response
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Middle Aged
  • Mastectomy
  • Inflammatory Breast Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Parrish, K. M., Thomas, S. M., Cartwright, S. B., van den Bruele, A. B., Zasloff, R., DiLalla, G. A., … Chiba, A. (2024). Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study. In Ann Surg Oncol (Vol. 31, pp. 8057–8067). United States. https://doi.org/10.1245/s10434-024-16026-w
Parrish, Kendra M., Samantha M. Thomas, Sara B. Cartwright, Astrid Botty van den Bruele, Rebecca Zasloff, Gayle A. DiLalla, Maggie L. DiNome, et al. “Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study.” In Ann Surg Oncol, 31:8057–67, 2024. https://doi.org/10.1245/s10434-024-16026-w.
Parrish KM, Thomas SM, Cartwright SB, van den Bruele AB, Zasloff R, DiLalla GA, et al. Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study. In: Ann Surg Oncol. 2024. p. 8057–67.
Parrish, Kendra M., et al. “Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study.Ann Surg Oncol, vol. 31, no. 12, 2024, pp. 8057–67. Pubmed, doi:10.1245/s10434-024-16026-w.
Parrish KM, Thomas SM, Cartwright SB, van den Bruele AB, Zasloff R, DiLalla GA, DiNome ML, Menendez CS, Rosenberger LH, Woriax HE, Hwang ES, Plichta JK, Chiba A. Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study. Ann Surg Oncol. 2024. p. 8057–8067.
Journal cover image

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

November 2024

Volume

31

Issue

12

Start / End Page

8057 / 8067

Location

United States

Related Subject Headings

  • Survival Rate
  • Retrospective Studies
  • Prognosis
  • Pathologic Complete Response
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Middle Aged
  • Mastectomy
  • Inflammatory Breast Neoplasms